chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Hearing loss and Tinnitus on both ears on the 3 day after the shot. Loud humming, buzzing, cricket sounds and ringing 24/7 Never have it before the vaccine Prednisone was given by ENT but so far no improvement.
fever, h/a, backache, abd soreness, diarrhea, chills, sweating;Temp to 104 on 11/9/99;went to civilian ER on 11/9/99 for eval & diagnostic tests;prescribed APAP & Ibuprofen & encourage fluid;
Pt received Pfizer x1.  Pt tested COVID + on 8/1/21 and admitted to hospital for COVID on 8/11/2021. Pt received remdesivir, tocilizumab and dexamethasone.
Numbing and tingling around mouth area, lightheadedness, dizziness, slight chills sore throat, tiredness, slight headache, injection site swelling and redness slight fast heartbeat,Light weakness
arm sore; This spontaneous report has been received from a lawyer, via a Plaintiff Fact Sheet regarding a case in litigation for zoster vaccine live (ZOSTAVAX) (2101USA009217), referring to an elderly male patient.  Information about medical history, concurrent conditions and concomitant therapies was not provided.   On 15-OCT-2020, the patient was vaccinated with measles, mumps, and rubella (Wistar RA 27-3) virus vaccine, live (manufacturer unknown) (strength, dose, route, lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient experienced arm sore. The outcome of the event was unknown. The causality assessment was related.  This case was split from a legal case regarding the same patient.; Sender's Comments:  US-009507513-2101USA009217: US-009507513-2104USA006940:
Persistent pain in my right  calf getting my prominent.  Wondering if its a blood clot.
Patient was given a full dose of the Pfizer adult vaccine for her second dose instead of the Pfizer PED vaccine. One hour after the dose, no symptoms were observed, however, the next morning when we touched based with the parents again, the father reported that she had a temperature around 100F, soreness in the left arm where the vaccine was administered, and fatigue, which we informed the parents to look out for after speaking to representatives from CDC and Pfizer regarding the incident. Recommended the parents to keep an eye on her and provide children's Tylenol to help with the fever; also to keep her hydrated during the day.  No other discomfort or symptoms reported by parents.
3/9/21 ER HPI Patient is a 71 y.o. female who presents with complaint of elevated blood pressure systolic of over 200 since last night.  Patient said that she has taken her blood pressure medications without much improvement.  The elevated blood pressure is associated with frontal headache.  No nausea vomiting, no dizziness, no chest pain, no cough or shortness of breath.  No fever or chills
Patient received GARDASIL injection with no initial problem. Patient stood-up, put on coat and stood in hallway for a minute and then felt dizzy an fell backwards onto floor.
aches and chills; aches and chills; problem sleeping; This spontaneous case was reported by a consumer and describes the occurrence of INSOMNIA (problem sleeping), PAIN (aches and chills) and CHILLS (aches and chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030m20a) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 12-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, the patient experienced INSOMNIA (problem sleeping). On 13-Feb-2021, the patient experienced PAIN (aches and chills) and CHILLS (aches and chills). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, INSOMNIA (problem sleeping), PAIN (aches and chills) and CHILLS (aches and chills) outcome was unknown.            Reporter did not allow further contact
More than 35 days between does 1 and dose 2; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 35 days between does 1 and dose 2) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029K20A and 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised. Concomitant products included GLIPIZIDE, METFORMIN, SIMVASTATIN, LISINOPRIL and LEVOTHYROXINE for an unknown indication.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Feb-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 35 days between does 1 and dose 2). On 28-Feb-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 35 days between does 1 and dose 2) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Caller reported that she have had the first two doses (Moderna) and experienced no problem.   This case was linked to MOD-2021-349550.
Severe pain, swelling, inflammation of left ankle, foot, base of toes. Unable to walk on that leg for 5 days, pain still persists with swelling and appears to now also impact Achilles tendon, heel, feet tendons,ligaments and thigh tendons, ligaments
Myalgia severe arm pain and immobility to appendage that had the injection Narrative:
Headache, redness, hot at injection site. Low grade fever, pain, red area spreading at injection site & had swelling big as grapefruit.
metallic taste; This is a spontaneous report from a Pfizer-sponsored program support from a contactable consumer (patient).   A 63 years old male patient received the second dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine, lot. EN5318) at single dose, on an unspecified date, for COVID-19 immunization. Relevant medical history and concomitant medications were unknown. The patient previously, on 19Feb2021, received the first dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine) at single dose, for COVID-19 immunization. After the first dose, the patient experienced soreness at point of injection. On an unspecified date, after the second dose, the patient experienced strong metallic taste. Clinical outcome of the adverse event was unknown at time of this report.   No follow-up attempts are needed, no further information expected.
After her second dose of COVID 19 vaccine (Moderna) she developed asthma flare/shortness of breath which lasted for several weeks. Optometry visit 4/20 Bilateral presbyopia ; Anatomical narrow angle and Irritation of both eyes  Pt prescribed ketotifen Telephone visit 4/21 pt states she had to stay 1 hour after receiving vaccine to be monitored. States has been having to take her albuterol more often and is having sob. Pt coughing on the phone. Advised pt go to ED to be seen asap. Unclear if pt went to ED.
Rash; urticaria-diffuse; This is a spontaneous report received from a contactable reporter(s) (Physician).  A 75-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 24Oct2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 75 years intramuscular, in right arm for covid-19 immunisation. The patient's relevant medical history included: "HTN" (unspecified if ongoing); "HLD" (unspecified if ongoing); "gout" (unspecified if ongoing). Concomitant medication(s) included: ALLOPURINOL; GLIPIZIDE; LISINOPRIL; FELODIPINE. Past drug history included: Hmg coa reductase inhibitors, reaction(s): "known allergies: HMG coa reductase inhibitors". Vaccination history included: Covid -19 vaccine (DOSE 3 (BOOSTER), SINGLE, Unknown manufacturer), for Covid-19 Immunization; Covid -19 vaccine (Primary Immunization Series Completed; Unknown manufacturer), for Covid-19 Immunization. The following information was reported: RASH (non-serious) with onset 24Oct2022, outcome "recovering"; URTICARIA (non-serious) with onset 24Oct2022, outcome "recovering", described as "urticaria-diffuse". The events "rash" and "urticaria-diffuse" required physician office visit. Therapeutic measures were taken as a result of rash, urticaria. Additional information:  treatment included topical, oral steroids. Covid wasn't tested post vaccination. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Has caused severe p.m.d.d.; depression symptoms.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 42 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 26Apr2021 09:30 (Lot number: Ew0177) at the age of 42 years as dose 1,single and administered in arm right, administration date 17May2021 09:30 (Lot number: Er8736) as dose 2,single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PREMENSTRUAL DYSPHORIC DISORDER (non-serious) with onset 30Apr2021 11:00, outcome "not recovered", described as "Has caused severe p.m.d.d."; DEPRESSION (non-serious) with onset 30Apr2021 11:00, outcome "not recovered", described as "depression symptoms". Therapeutic measures were not taken as a result of premenstrual dysphoric disorder, depression.  Additional information: The patient had no other vaccine in four weeks nor other medication in two weeks. The patient did not have covid prior to vaccination or was tested post vaccination. The patient had no known allergies.  Follow-up attempts are completed. No further information is expected.
Patient's mother reported approx. 50 pin-sized pox-like areas scattered on bilat. arms, legs, feet, hands, buttocks and mouth appearing approx. 3 hrs. of receiving vaccinations on 7-17-12 at 2:45 pm. Temp of 101 degrees on 7-17-12 (in the evening) but afebrile since then. Areas starting to crust over.
develop an upper respiratory infection; Initial information received on 23-Oct-2019 regarding an unsolicited valid non serious case received from a other health professional.  This case is linked to cases 2019SA301094 and 2019SA301095 (same reporter).  This case involves unknown demographic patient who experienced upper respiratory infection (upper respiratory tract infection), while patient received vaccine INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE lot number not reported via unknown route in unknown administration site.  On an unknown date, the patient developed a non serious upper respiratory infection (upper respiratory tract infection) unknown latency following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE.   Other relevant tests were not reported.  Final diagnosis was upper respiratory infection.  It was not reported if the patient received a corrective treatment.  The patient outcome was reported as unknown.   Information on the batch number was requested.
Rash with pruritus on torso chest back and arms. Improving now appear like dark circular patches on abdomen. No longer pruritic
pt recvd vax;T 104.8 p/ 2 days; to er;
reports that he tested positive on PCR test performed at physician office 8/28/2022.
Received a call from Mother stating she noticed this morning, 3/14/18, a red, hot to touch, hard lump the diameter of a baseball about 1 1/2 inches below injection site (right deltoid muscle).
expired vaccine administered to patients; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired vaccine administered to patients) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 062E21A and 088D21A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Sep-2021 at 9:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Sep-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired vaccine administered to patients). On 23-Sep-2021, EXPIRED PRODUCT ADMINISTERED (expired vaccine administered to patients) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medications were provided.  The vial was stored in refrigerator on 14 Sep 2021 and  vial was punctured  on 22 Sep 2021 at 6 am . The vial did not undergo any temperature excursions. The person who pre - draw the doses took around 6- 10 min, then the syringes were stored in the fridge.   This case was linked to MOD-2021-328726 (Patient Link).
Patient states that she has been having bilateral eye swelling since 1/11/21 around 8 am.
The injection was in the shoulder.  Pain began less than one day later.  I waited for the pain to resolve.  It has not.  My shoulder is still sore.  The pain is getting progressively worse and it now hurts to comb my hair, it hurts to raise my arm to put dishes in the cabinet, and it is hard to carry lift and carry objects of 8 ounces more.  This pain also make it difficult to sleep through the night.
Patient starting  feeling dizzy after the administration and also complained of headache. Healthcare professional checked the patient's blood pressure which was normal. After about 20 minutes of observation, patient was not getting better and EMS was called .
I received my second Zostavax vaccination. For the next 3 days, I had muscle pain all over but mostly in my lower back, which was not reduced by naproxen or acetaminophen; fever enough to soak me in sweat alternating with chills enough to wear and zip up my coat in a typical office setting; and fatigue nearly enough to fall asleep at my desk. I was able to push through with typical duties but for a reduced duration, like leaving work early.
difficulty breathing; Swelling of the face and at the injection site; Swelling of the face and at the injection site; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Oct2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 78 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE; MANUFACTURER UNKNOWN; Lot number: unknown), for COVID-19 Immunization; Covid-19 vaccine (DOSE 2, SINGLE; MANUFACTURER UNKNOWN; Lot number: unknown), for COVID-19 Immunization. The following information was reported: SWELLING FACE (non-serious), VACCINATION SITE SWELLING (non-serious) all with onset Oct2022, outcome "unknown" and all described as "Swelling of the face and at the injection site"; DYSPNOEA (non-serious) with onset Oct2022, outcome "unknown", described as "difficulty breathing".  Additional information: Patient just wanted to report the reactions she had with the booster. She took the booster on 06Oct this year (Later clarified as 06Oct2022). She had difficulty breathing, swelling of the face and at the injection site. The Pfizer, she took the other 4 (Further clarifications unknown) and this was the third booster. Call got disconnected. Call back was done to gather more information however unsuccessful. Thus, further probing was not done. Product details (NDC# and UPC#) and Pharmacy details could not be probed. Hence limited information was available over the call.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
a few months after the second dose I started having heart palpitations, after extensive health tests including HSCRP test (high), Cholesterol (very high); Calcium score (high); stress test (abnormal) and a nuclear stress test (abnormal and detected Small vessel disease)
Severe pain and swelling in left thigh. Won't walk and high fever 103-104. Red marks and dots on leg. Very uncomfortable. Non weight bearing on the left leg.
Patient had dizziness, nausea a few minutes after vaccine administered. Patient felt better after vomiting x1. Undigested food, no bleeding -- patient had spicey rice prior to coming to vaccine clinic. Given water. Patient stable, released from vaccination site.
nerve type pain in dermatome of previous HZV infection ; intermittent ; started within 2 weeks of Moderna COVID booster ( full dose) and intermittent x 5 months ; no rash
31 year-old Hispanic female who post vaccination developed urticaria on the neck, face, eyes, chest,  arms thighs and legs.  13:45 25 mg oral Benadryl with observation .   Signs and symptoms were still progressing so at 1350  additional 25 mg of oral Benadryl was administered.  Symptoms were still progressing  and patenting starting complaining of shortness of breath and chest tightness so at 13:55 0.3 mg of 1:0000 Epinephrine was administered  with improvement of symptoms.  At 14::21 the patient started relapsing with SOB, Chest pain and urticaria along with increase in itchiness..  An addition 0.3 mg of Epinephrine was administered.   Vitals remained stable throughout event 140/79, Resp Rate 24, pulse rate varies between 100-140 and patient oxygen saturation remained 96-100% FIO2 on room air.  Patient was transported to
Two doses of varicella vaccine were given. One single dose and a dose in the PROQUAD vaccine. Child had prolonged subjective fever which resolved with time. No rash on other complications.
Had varicella vaccine on 7/16/04. Now has rash all over; bumps. Drinking, playing; symptomatic treatment. 15 vesicular, erythematous base lesion 2 weeks after shots. Fever up to 100.
Total lack of energy after 1st dose; Slight cough after 1st dose; Shivering after 1st dose; Feeling horrible since 1st dose; Feels like he has COVID-19 again after 1st dose, exposed to COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (Feeling horrible since 1st dose), ASTHENIA (Total lack of energy after 1st dose), COUGH (Slight cough after 1st dose), EXPOSURE TO SARS-COV-2 (Feels like he has COVID-19 again after 1st dose, exposed to COVID-19) and CHILLS (Shivering after 1st dose) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included COVID-19 on 01-Oct-2020.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Mar-2021, the patient experienced EXPOSURE TO SARS-COV-2 (Feels like he has COVID-19 again after 1st dose, exposed to COVID-19). On 24-Mar-2021, the patient experienced FEELING ABNORMAL (Feeling horrible since 1st dose). On an unknown date, the patient experienced ASTHENIA (Total lack of energy after 1st dose), COUGH (Slight cough after 1st dose) and CHILLS (Shivering after 1st dose). At the time of the report, FEELING ABNORMAL (Feeling horrible since 1st dose), ASTHENIA (Total lack of energy after 1st dose), COUGH (Slight cough after 1st dose), EXPOSURE TO SARS-COV-2 (Feels like he has COVID-19 again after 1st dose, exposed to COVID-19) and CHILLS (Shivering after 1st dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medication were reported. Treatment medication was not provided.
IMZ was administered @ 4:09pm, patient felt dizzy @ 4:11pm, 911 was called @ 4:12, EMS arrived at 4:17pm, patient was ok by the time EMS arrived. Patient was laid on the floor until EMS arrived, no treatment occurred as patient was ok within 30 secs to 1 min after experiencing symptoms. Patient denied EMS medical treatment.
I had noticed symptoms beginning on Sunday October 16th. Before that I was sneezing but didn't think anything of it. I noticed a tickle in my throat and 2 days later as we were traveling, my sneezing had continued and I had a runny nose, headache and slight sore throat. So I went to an urgent care to test for COVID-19 just in case and it was negative. I was diagnosed with a cold which I haven't had in several years. I hadn't been sick in any in so long. Today some of the symptoms have resulted but the runny nose has continued and my voice has been affected. Seems what was going on has moved down to my chest. I can breathe fine and my energy level is fine. The family we were visiting had been exposed to RSV.
I broke out in a rash, red bumps in between my fingers of my hands. They were lumpy with bumps and they also radiated to my shoulders. The front of my legs up to my knees also broke out in a rash.  I went to the ER but the doctor could not tell me why i got this. He thought it was eczema. He prescribed me steroids.
Slight fever, pain around injection site in arm, fatigue,  tightness in chest, difficulty taking deep breaths,  throat partially closing.
left arm soreness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (left arm soreness) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Cyanotic heart disease.    On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Feb-2021, the patient experienced PAIN IN EXTREMITY (left arm soreness). At the time of the report, PAIN IN EXTREMITY (left arm soreness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Feb-2021, Body temperature: 97.1-97.9 f 97.1-97.9 F but that's normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication taken was Aspirin for Cyanotic heart disease. No treatment medication was reported.   This case was linked to MOD-2021-097104.   Most recent FOLLOW-UP information incorporated above includes: On 28-Apr-2021
stroke; This spontaneous case was reported by a consumer and describes the occurrence of CEREBROVASCULAR ACCIDENT (stroke) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced CEREBROVASCULAR ACCIDENT (stroke) (seriousness criteria medically significant and life threatening). At the time of the report, CEREBROVASCULAR ACCIDENT (stroke) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       concomitant information was not provided by reporter No treatment information was provided.  Very limited information regarding the event has been provided at this time. No further information is expected as follow up consent was not obtained.; Sender's Comments: Very limited information regarding the event has been provided at this time. No further information is expected as follow up consent was not obtained.
Patient fainted after receiving first dose of moderna, patient came to immediately with no confusion, he was able to answer all questions
Left axillary lymph node enlargement - began day 2 after vaccination (1/1/21) and continues as of today 1/8/21.  Left neck lymph node enlargement and sore throat began 1/6/21, pustule in left throat 1/7/21.
Presyncope (lightheadedness, nausea, blurry vision). Normal vitals. Symptoms improved with supine rest and oral rehydration.